Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

BACKGROUND: Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ressler, Julia Maria, Karasek, Matthias, Koch, Lukas, Silmbrod, Rita, Mangana, Joanna, Latifyan, Sofiya, Aedo-Lopez, Veronica, Kehrer, Helmut, Weihsengruber, Felix, Koelblinger, Peter, Posch, Christian, Kofler, Julian, Michielin, Olivier, Richtig, Erika, Hafner, Christine, Hoeller, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898852/
https://www.ncbi.nlm.nih.gov/pubmed/33608376
http://dx.doi.org/10.1136/jitc-2020-001701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898852/
https://www.ncbi.nlm.nih.gov/pubmed/33608376
http://dx.doi.org/10.1136/jitc-2020-001701

Ejemplares similares